Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs ...

Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral ...

"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes ...

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to ...

Here are the top 5 articles from 2024 reported on Oncology Nursing News. Opinion: The Media May Have Oversold AOH1996, City ...

Lenvatinib showed a median PFS of 5.4 months in advanced HCC patients following treatment with atezolizumab/bevacizumab, meeting the primary endpoint. Second-line ...

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...

Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) was approved by the FDA for subcutaneous injection across approved solid tumor indications for nivolumab (Opdivo). The FDA granted approval to ...

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...